COVID-19 Primary Care Platform for Early Treatment and Recovery (COPPER) Study
Status:
Terminated
Trial end date:
2021-04-23
Target enrollment:
Participant gender:
Summary
The COVID-19 coronavirus has led to a global pandemic of respiratory diseases with an
increase in hospitalization and death risk. To keep COVID-19 manageable for healthcare, early
treatment is urgently needed to avoid hospitalization. Dexamethasone can dampen the
exaggerated cytokine response to COVID-19 and is a promising agent for preventing disease
aggravation, hospitalization and death. However, the evidence on the effectiveness, safety
and cost-effectiveness of dexamethasone treatment in primary care is inconclusive.